Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Oct;119(3):609–615. doi: 10.1111/j.1476-5381.1996.tb15716.x

Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.

P S Pagel 1, D A Hettrick 1, D C Warltier 1
PMCID: PMC1915696  PMID: 8894186

Abstract

1. The distribution of cardiac output during administration of levosimendan, a new myofilament calcium sensitizer, is unknown. We examined and compared the effects of levosimendan, pimobendan, and milrinone on regional tissue perfusion by use of the radioactive microsphere technique in barbiturate-anaesthetized dogs. 2. Haemodynamics and regional blood flow were determined before and during infusions of levosimendan (0.75, 1.5, and 3.0 micrograms kg-1 min-1), pimobendan (10, 20, and 40 micrograms kg-1 min-1), or milrinone (1.0, 2.0, and 4.0 micrograms kg-1 min-1). 3. All three drugs caused similar increases in heart rate, cardiac output, and left ventricular +dP/dt and decreases in end-diastolic pressure and systemic vascular resistance. No changes in subendocardial, midmyocardial, and subepicardial blood flow occurred during administration of levosimendan. However, a redistribution of blood flow from subendocardium to subepicardium was observed. Pimobendan increased midmyocardial and subepicardial blood flow and reduced the endo/epi ratio to a greater degree than levosimendan. Milrinone did not affect myocardial perfusion. 4. Levosimendan increased blood flow to the renal medulla and decreased renal medullary and cortical vascular resistance. Levosimendan increased blood flow to the small intestine and liver and reduced vascular resistance in these organs. Pimobendan increased hepatic blood flow to a greater degree than levosimendan but did not alter small intestinal perfusion. All three drugs decreased splenic blood flow to similar degrees. Levosimendan and pimobendan reduced cerebral vascular resistance. Levosimendan and milrinone reduced skeletal muscle vascular resistance. 5. The results indicate that levosimendan, pimobendan, and milrinone cause subtlety different alterations in regional tissue perfusion while producing similar haemodynamic effects.

Full text

PDF
609

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumann G., Ningel K., Permanetter B. Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1989 May;13(5):730–738. [PubMed] [Google Scholar]
  2. Borow K. M., Come P. C., Neumann A., Baim D. S., Braunwald E., Grossman W. Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease. Am J Cardiol. 1985 Apr 15;55(9):1204–1209. doi: 10.1016/0002-9149(85)90664-2. [DOI] [PubMed] [Google Scholar]
  3. Böhm M., Morano I., Pieske B., Rüegg J. C., Wankerl M., Zimmermann R., Erdmann E. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res. 1991 Mar;68(3):689–701. doi: 10.1161/01.res.68.3.689. [DOI] [PubMed] [Google Scholar]
  4. Colucci W. S., Wright R. F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. N Engl J Med. 1986 Jan 30;314(5):290–299. doi: 10.1056/NEJM198601303140506. [DOI] [PubMed] [Google Scholar]
  5. Domenech R. J., Hoffman J. I., Noble M. I., Saunders K. B., Henson J. R., Subijanto S. Total and regional coronary blood flow measured by radioactive microspheres in conscious and anesthetized dogs. Circ Res. 1969 Nov;25(5):581–596. doi: 10.1161/01.res.25.5.581. [DOI] [PubMed] [Google Scholar]
  6. Drexler H., Höing S., Faude F., Wollschläger H., Just H. Central and regional vascular hemodynamics following intravenous milrinone in the conscious rat: comparison with dobutamine. J Cardiovasc Pharmacol. 1987 May;9(5):563–569. doi: 10.1097/00005344-198705000-00010. [DOI] [PubMed] [Google Scholar]
  7. Edes I., Kiss E., Kitada Y., Powers F. M., Papp J. G., Kranias E. G., Solaro R. J. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995 Jul;77(1):107–113. doi: 10.1161/01.res.77.1.107. [DOI] [PubMed] [Google Scholar]
  8. Einzig S., Rao G. H., Pierpont M. E., White J. G. Acute effects of amrinone on regional myocardial and systemic blood flow distribution in the dog. Can J Physiol Pharmacol. 1982 Jun;60(6):811–818. doi: 10.1139/y82-113. [DOI] [PubMed] [Google Scholar]
  9. Fujino K., Sperelakis N., Solaro R. J. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res. 1988 Nov;63(5):911–922. doi: 10.1161/01.res.63.5.911. [DOI] [PubMed] [Google Scholar]
  10. Hagemeijer F., Brand H. J., van Mechelen R. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1989 Mar 1;63(9):571–576. doi: 10.1016/0002-9149(89)90901-6. [DOI] [PubMed] [Google Scholar]
  11. Haikala H., Kaivola J., Nissinen E., Wall P., Levijoki J., Lindén I. B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995 Sep;27(9):1859–1866. doi: 10.1016/0022-2828(95)90009-8. [DOI] [PubMed] [Google Scholar]
  12. Haikala H., Nissinen E., Etemadzadeh E., Levijoki J., Lindén I. B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995 May;25(5):794–801. doi: 10.1097/00005344-199505000-00016. [DOI] [PubMed] [Google Scholar]
  13. Hajjar R. J., Gwathmey J. K. Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view. Cardiovasc Drugs Ther. 1991 Dec;5(6):961–965. doi: 10.1007/BF00143520. [DOI] [PubMed] [Google Scholar]
  14. Harkin C. P., Pagel P. S., Tessmer J. P., Warltier D. C. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol. 1995 Aug;26(2):179–188. doi: 10.1097/00005344-199508000-00002. [DOI] [PubMed] [Google Scholar]
  15. Hasenfuss G., Holubarsch C., Heiss H. W., Just H. Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Am Heart J. 1989 Sep;118(3):512–519. doi: 10.1016/0002-8703(89)90266-4. [DOI] [PubMed] [Google Scholar]
  16. Jaski B. E., Fifer M. A., Wright R. F., Braunwald E., Colucci W. S. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest. 1985 Feb;75(2):643–649. doi: 10.1172/JCI111742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Katz S. D., Kubo S. H., Jessup M., Brozena S., Troha J. M., Wahl J., Cohn J. N., Sonnenblick E. H., LeJemtel T. H. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J. 1992 Jan;123(1):95–103. doi: 10.1016/0002-8703(92)90752-h. [DOI] [PubMed] [Google Scholar]
  18. Lilleberg J., Sundberg S., Häyhä M., Akkila J., Nieminen M. S. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol. 1994;47(3):267–274. doi: 10.1007/BF02570507. [DOI] [PubMed] [Google Scholar]
  19. Lilleberg J., Sundberg S., Nieminen M. S. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol. 1995;26 (Suppl 1):S63–S69. [PubMed] [Google Scholar]
  20. Monrad E. S., McKay R. G., Baim D. S., Colucci W. S., Fifer M. A., Heller G. V., Royal H. D., Grossman W. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation. 1984 Dec;70(6):1030–1037. doi: 10.1161/01.cir.70.6.1030. [DOI] [PubMed] [Google Scholar]
  21. Pagel P. S., Harkin C. P., Hettrick D. A., Warltier D. C. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology. 1994 Oct;81(4):974–987. doi: 10.1097/00000542-199410000-00025. [DOI] [PubMed] [Google Scholar]
  22. Pagel P. S., Harkin C. P., Hettrick D. A., Warltier D. C. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs. J Pharmacol Exp Ther. 1995 Oct;275(1):127–135. [PubMed] [Google Scholar]
  23. Pelc L. R., Gross G. J., Warltier D. C. Effects of KB-944, a novel calcium antagonist, in several models of canine myocardial ischemia. J Pharmacol Exp Ther. 1986 Jul;238(1):113–118. [PubMed] [Google Scholar]
  24. Piscione F., Jaski B. E., Wenting G. J., Serruys P. W. Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failing human heart. J Am Coll Cardiol. 1987 Dec;10(6):1294–1302. doi: 10.1016/s0735-1097(87)80134-1. [DOI] [PubMed] [Google Scholar]
  25. Pollesello P., Ovaska M., Kaivola J., Tilgmann C., Lundström K., Kalkkinen N., Ulmanen I., Nissinen E., Taskinen J. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994 Nov 18;269(46):28584–28590. [PubMed] [Google Scholar]
  26. Pouleur H., Hanet C., Schröder E., Col J., Van Mechelen H., Etienne J., Rousseau M. F. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. J Cardiovasc Pharmacol. 1989;14 (Suppl 2):S18–S22. [PubMed] [Google Scholar]
  27. Remme W. J., Wiesfeld A. C., Look M. P., Kruyssen H. A. Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction. J Cardiovasc Pharmacol. 1989;14 (Suppl 2):S41–S44. [PubMed] [Google Scholar]
  28. Solaro R. J., Fujino K., Sperelakis N. The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments. J Cardiovasc Pharmacol. 1989;14 (Suppl 2):S7–12. [PubMed] [Google Scholar]
  29. Sundberg S., Lilleberg J., Nieminen M. S., Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol. 1995 May 15;75(15):1061–1066. doi: 10.1016/s0002-9149(99)80725-5. [DOI] [PubMed] [Google Scholar]
  30. Thormann J., Schlepper M., Kramer W., Gottwik M., Kindler M. Effects of AR-L 115 BS (Sulmazol), a new cardiotonic agent, in coronary artery disease: improved ventricular wall motion, increased pump function and abolition of pacing-induced ischemia. J Am Coll Cardiol. 1983 Aug;2(2):332–337. doi: 10.1016/s0735-1097(83)80171-5. [DOI] [PubMed] [Google Scholar]
  31. Verdouw P. D., Hartog J. M., Duncker D. J., Roth W., Saxena P. R. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol. 1986 Jul 15;126(1-2):21–30. doi: 10.1016/0014-2999(86)90733-8. [DOI] [PubMed] [Google Scholar]
  32. Walter M., Liebens I., Goethals H., Renard M., Dresse A., Bernard R. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. Br J Clin Pharmacol. 1988 Mar;25(3):323–329. doi: 10.1111/j.1365-2125.1988.tb03310.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. van Meel J. C., Zimmermann R., Diederen W., Erdman E., Mrwa U. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole. Biochem Pharmacol. 1988 Jan 15;37(2):213–220. doi: 10.1016/0006-2952(88)90720-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES